Brief: Lipigon Announces Positive Top-Line Data From Phase I Clinical Study Of Lipisense

Lipigon Pharmaceuticals AB

05/10/2022 12:32

Oct 5 (Reuters) - Lipigon Pharmaceuticals AB  LPGO.ST :
    * ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE I CLINICAL
STUDY OF
LIPISENSE
    * POSITIVE TOP-LINE RESULTS FROM A PHASE I SAD STUDY OF ITS
INVESTIGATIONAL MEDICINE LIPISENSE IN HEALTHY VOLUNTEERS
    * "IT IS NOT UNLIKELY THAT WE WILL BE ABLE TO START PHASE II
STUDY
NEXT YEAR," SAYS CEO STEFAN K. NILSSON
    * PHASE I SAD (SINGLE ASCENDING DOSE) STUDY DEMONSTRATED
THAT
LIPISENSE HAS A FAVORABLE SAFETY AND PHARMACOKINETIC PROFILE.
LIPISENSE WAS WELL TOLERATED, WITH NO SERIOUS ADVERSE EVENTS
REPORTED

Source text for Eikon:  ID:nBQN2yZ9g 
Further company coverage:  LPGO.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))